Toward repurposing drugs for CSC inhibition, we initially screened an NCI Diversity library of FDA-approved drugs using H460 human lung cancer cell line which contains mutations in the clinically relevant genes EGFR and KRAS (Fig. S4). The gene discussed is KRAS; the disease is lung cancer.